ADMA Biologics to Report Business Highlights and Second Quarter 2020 Financial Results on August 5, 2020

Rhea-AI Summary

ADMA Biologics, Inc. (ADMA) announced a live conference call scheduled for August 5, 2020, at 4:30 p.m. ET to discuss its business highlights and financial results for Q2 2020, ending June 30, 2020. The call can be accessed via phone or through an audio webcast available on ADMA's investor relations website. The company is focused on manufacturing and developing plasma-derived biologics targeting immunodeficient patients.

RAMSEY, N.J. and BOCA RATON, Fla., July 29, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the Company will host a live conference call and audio webcast on Wednesday, August 5, 2020 at 4:30 p.m. ET, to discuss its business highlights and financial results for the second quarter ended June 30, 2020.

To access the conference call, please dial (855) 884-8773 (local) or (615) 622-8043 (international) at least 10 minutes prior to the start time and refer to conference ID 8992308. A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

COMPANY CONTACT:

Brian Lenz

Executive Vice President and Chief Financial Officer | 201-478-5552 | www.admabiologics.com 

INVESTOR RELATIONS CONTACT:

Sam Martin

Managing Director, Argot Partners | 212-600-1902 | sam@argotpartners.com

FAQ

What is the date of ADMA's upcoming conference call?

ADMA's upcoming conference call is scheduled for August 5, 2020.

What financial results will ADMA discuss in the conference call?

ADMA will discuss its financial results for the second quarter ending June 30, 2020.

How can I access the ADMA conference call?

You can access the ADMA conference call by dialing provided phone numbers or via an audio webcast on their investor relations website.